ERBB2 and neoplasm: Trastuzumab deruxtecan (DS-8201, T-Dxd) is an antibody-drug coupling drug consisting of an anti-HER2 antibody, a cleavable tetrapeptide linker, and a cytotoxic topoisomerase I inhibitor to achieve precise tumor cell killing (17).